Kevin has served as a member of the Board of Directors of Silk Road Medical, a publicly traded company focused on reducing the risk of stroke, since December 2020.

From July 2020 to September 2023, Kevin served as President of Aldevron, a privately held genomics company that was acquired by Danaher Corporation in August 2021.

Prior to joining Aldevron, Kevin spent 25 years at Boston Scientific Corporation. During his last nine years at Boston Scientific, Kevin served as Executive Vice President and Global President of the Interventional Cardiology division. Kevin has served on the board of directors of Shockwave Medical, Inc., since June 2023.